Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT04614636
Other study ID # FT538-101
Secondary ID
Status Terminated
Phase Phase 1
First received
Last updated
Start date October 17, 2020
Est. completion date August 8, 2023

Study information

Verified date September 2023
Source Fate Therapeutics
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a Phase I dose-finding study of FT538 as monotherapy in acute myeloid leukemia (AML) and in combination with monoclonal antibodies in multiple myeloma (MM). The study will consist of a dose-escalation stage and an expansion stage where participants will be enrolled into indication-specific cohorts.


Recruitment information / eligibility

Status Terminated
Enrollment 42
Est. completion date August 8, 2023
Est. primary completion date July 13, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Diagnosis of one of the following by treatment regimen: - Regimen A (FT538 monotherapy in r/r AML) - Primary refractory AML, or - Relapsed AML, defined as not in CR after one or more re-induction attempts; if >60 years of age, prior re-induction therapy is not required - Regimens B or C (FT538 + mAb in r/r MM) - Regimen B only: MM that has relapsed or progressed after at least two lines of therapies, including a proteasome inhibitor and an immunomodulatory drug - Regimen C only: MM that has relapsed or progressed after proteasome inhibitor therapy, and immunomodulatory therapy - Regimen B and Regimen C: Measurable disease as defined in the protocol 2. Capable of giving signed informed consent 3. Agreement to comply with study procedures as described in the Schedule of Activities 4. Agrees to contraceptive use as described in the protocol Exclusion Criteria: 1. Females who are pregnant or breastfeeding 2. ECOG Performance Status = 2 3. Evidence of insufficient hematologic function as defined in the protocol 4. Evidence of insufficient organ function defined as defined by the protocol 5. Clinically significant cardiovascular disease as defined by the protocol 6. Known active central nervous system (CNS) involvement by malignancy 7. Non-malignant CNS disease such as stroke, epilepsy, CNS vasculitis, or neurodegenerative disease or receipt of medications for these conditions in the 2-year period leading up to study enrollment 8. Currently receiving or likely to require systemic immunosuppressive therapy for any reason during the treatment period 9. Clinically significant infections including HIV, HBV and HCV 10. Live vaccine <6 weeks prior to start of lympho-conditioning 11. Receipt of an allograft organ transplant 12. Prior allogeneic HSCT or allogeneic CAR-T within 6 months of Day 1, or ongoing requirement for systemic graft-versus-host therapy 13. Known allergy to albumin (human) or DMSO 14. Presence of any medical or social issues that are likely to interfere with study conduct or may cause increased risk to subject 15. Any medical condition or clinical laboratory abnormality that per investigator or Medical Monitor judgement precludes safe participation in and completion of the study, or which could affect compliance with protocol conduct or interpretation of results Exclusion Criteria Specific to Regimen A (r/r AML) 16. Diagnosis of promyelocytic leukemia with t(15;17) translocation 17. Receipt of any biological therapy, chemotherapy, or radiation therapy, except for palliative purposes, within 2 weeks prior to Day 1 or five half-lives, whichever is shorter; or any investigational therapy within 28 days prior to Day 1 Exclusion Criteria Specific to Regimens B and C (r/r MM) 18. Plasma cell leukemia defined as a plasma cell count >2000/mm3 19. Leptomeningeal involvement of MM 20. Receipt of any biological therapy, chemotherapy, or radiation therapy, except for palliative purposes, within 2 weeks prior to Day 1 or five half-lives, whichever is shorter; or any investigational therapy within 28 days prior to the first dose of mAb 21. Allergy or hypersensitivity to antibodies or antibody-related proteins

Study Design


Intervention

Drug:
FT538
Experimental Interventional Therapy, Allogeneic Cell Therapy NK Cell
Cyclophosphamide
Lympho-conditioning Agent
Fludarabine
Lympho-conditioning Agent
Daratumumab
Monoclonal Antibody, CD38, Anti-CD38
Elotuzumab
Monoclonal Antibody

Locations

Country Name City State
United States St. David's South Austin Medical Center Austin Texas
United States Colorado Blood Cancer Institute Denver Colorado
United States MD Anderson Cancer Center Houston Texas
United States University of Minnesota Masonic Cancer Center Minneapolis Minnesota
United States Sarah Cannon Research Institute at Tennessee Oncology Nashville Tennessee
United States Memorial Sloan Kettering Cancer Center New York New York
United States Washington University Saint Louis Missouri
United States Texas Transplant Institute San Antonio Texas

Sponsors (1)

Lead Sponsor Collaborator
Fate Therapeutics

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence of dose-limiting toxicities (DLTs) within each dose level cohort Cycle 1, Up to Day 29
Primary Nature of dose-limiting toxicities within each dose level cohort Cycle 1, Up to Day 29
Secondary Incidence, nature, and severity of adverse events (AEs) of FT538 as monotherapy in r/r AML and in combination with daratumumab or elotuzumab in r/r multiple myeloma Up to 5 years
Secondary Objective response rate (ORR) of FT538 as monotherapy in r/r AML and in combination with daratumumab or elotuzumab in r/r MM Proportion of subjects who achieve a CR, CRMRD-, CRi, MLFS, or PR, as determined by the investigator according to 2017 ELN criteria for AML, and the proportion of subjects with a best overall response of sCR, CR, VGPR, or PR, as determined by the investigator according to standard IMWG for MM response criteria From baseline tumor assessment up to approximately 2 years after last dose of FT538
Secondary Duration of response (DOR) of FT538 in combination with daratumumab or elotuzumab in r/r MM Defined as the duration from the first occurrence of a documented objective response until the time of disease progression or relapse, or death due to progressive disease, as determined by the investigator according to standard IMWG response criteria Up to 15 years
Secondary Progression-free survival (PFS) of FT538 in combination with daratumumab or elotuzumab in r/r MM Defined as the time from first dose of study treatment to disease progression or relapse, or to the day of death from any cause, as determined by the investigator according to standard IMWG response criteria Up to 15 years
Secondary Relapse-free survival (RFS) of FT538 as monotherapy in r/r AML and in combination with daratumumab or elotuzumab in r/r MM Defined as the time from initial CR (including CRMRD-, CR, and CRi) to hematologic relapse or death due to any cause, as determined by the investigator according to 2017 ELN criteria for AML, and defined as the duration from the start of sCR or CR until the time of relapse from sCR or CR, as determined by the investigator according to standard IMWG response criteria for MM Up to 15 years
Secondary Event-free survival (EFS) of FT538 as monotherapy in r/r AML defined as the time from first dose of lympho-conditioning to the date of PD, or relapse from CR or CRi, or death from any cause, according to 2017 ELN criteria Up to 15 years
Secondary Overall survival (OS) of FT538 as monotherapy in r/r AML and in combination with daratumumab or elotuzumab in r/r MM defined as the time from first dose of lympho-conditioning to death from any cause Up to 15 years
Secondary Time-to-best response of FT538 as monotherapy in r/r AML defined as the time from first dose of lympho-conditioning to best response Up to 15 years
Secondary Determination of the pharmacokinetics (PK) of FT538 cells in peripheral blood The PK of FT538 in peripheral blood will be reported as the relative percentage of product (FT538) DNA versus patient DNA (% chimerism) measured from blood samples at the specified time points Study Days: 1, 2, 4, 8, 11, 15, 18, 22, 29
See also
  Status Clinical Trial Phase
Recruiting NCT05027594 - Ph I Study in Adult Patients With Relapsed or Refractory Multiple Myeloma Phase 1
Completed NCT02412878 - Once-weekly Versus Twice-weekly Carfilzomib in Combination With Dexamethasone in Adults With Relapsed and Refractory Multiple Myeloma Phase 3
Completed NCT01947140 - Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies Phase 1/Phase 2
Recruiting NCT05971056 - Providing Cancer Care Closer to Home for Patients With Multiple Myeloma N/A
Recruiting NCT05243797 - Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation Phase 3
Active, not recruiting NCT04555551 - MCARH109 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of Multiple Myeloma Phase 1
Recruiting NCT05618041 - The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies N/A
Active, not recruiting NCT03844048 - An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial Phase 3
Recruiting NCT03412877 - Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer Phase 2
Completed NCT02916979 - Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG Phase 1
Recruiting NCT03570983 - A Trial Comparing Single Agent Melphalan to Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) as a Preparative Regimen for Patients With Multiple Myeloma Undergoing High Dose Therapy Followed by Autologous Stem Cell Reinfusion Phase 2
Terminated NCT03399448 - NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells) Phase 1
Completed NCT03665155 - First-in- Human Imaging of Multiple Myeloma Using 89Zr-DFO-daratumumab, a CD38-targeting Monoclonal Antibody Phase 1/Phase 2
Completed NCT02812706 - Isatuximab Single Agent Study in Japanese Relapsed AND Refractory Multiple Myeloma Patients Phase 1/Phase 2
Active, not recruiting NCT05024045 - Study of Oral LOXO-338 in Patients With Advanced Blood Cancers Phase 1
Active, not recruiting NCT03989414 - A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM) Phase 1/Phase 2
Active, not recruiting NCT03792763 - Denosumab for High Risk SMM and SLiM CRAB Positive, Early Myeloma Patients Phase 2
Withdrawn NCT03608501 - A Study of Ixazomib, Thalidomide and Dexamethasone in Newly Diagnosed and Treatment-naive Multiple Myeloma (MM) Participants Non-eligible for Autologous Stem-cell Transplantation Phase 2
Recruiting NCT04537442 - Clinical Study to Evaluate the Safety and Efficacy of IM21 CAR-T Cells in the Treatment of Elderly Patients With Relapsed or Refractory Multiple Myeloma Phase 1
Completed NCT02546167 - CART-BCMA Cells for Multiple Myeloma Phase 1

External Links